Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTERNATE: Neoadjuvant Endocrine Therapy in Postmenopausal Women with ER+ Breast Cancer
NCT01953588Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2014
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of fulvestrant in breast cancer, sponsored by Cancer and Leukemia Group B. Started Feb 2014; status: active, not recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01953588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01953588.